

REQUEST FOR

In re Application

Application Number

07/310,252

Filed

2/13/89

GRANT NUMBER

Examiner

185

38

Paper No. ~~429~~

#34

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(vi) to the application file record of the above identified ABANDONED application, which is: (CHECK ONE):

(A) referred to in United States Patent Number 51693,761, column _____
 (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.14(f), Application No. _____, files _____ on page _____
 (C) an application that claims the benefit of the filing date of an application that is open to inspection, i.e., Application No. _____, files _____
 (D) an application in which the applicant has filed an authorization to pay open the same application to the public.

Please direct any correspondence concerning this request to the following address:

Sunny Down
Signature

Sunny Down
Typed or printed name

12-17-99

Date

RECEIVED	FOR PTO USE ONLY
DEC 21 1999	Approved by: _____
File Information Unit	
Unit: _____	

SEARCHED SERIALIZED INDEXED COMPUTERIZED FILED FEB 13 1989
BY: [Signature] USPTO - WASHDC
U.S. GOVERNMENT PRINTING OFFICE: 1995 500-100-02544
2025 RELEASE UNDER E.O. 14176

US005693761A

United States Patent [19]

Queen et al.

[11] Patent Number: 5,693,761
 [45] Date of Patent: Dec. 2, 1997

[54] POLYNUCLEOTIDES ENCODING
 IMPROVED HUMANIZED
 IMMUNOGLOBULINS

[75] Inventors: Cary L. Queen, Los Altos; William P. Schneider, Mountain View; Harold E. Schlick, Belmont, all of Calif.

[73] Assignee: Protein Design Labs, Inc., Mountain View, Calif.

[21] Appl. No.: 474,040

[22] Filed: Jun. 7, 1995

Related U.S. Application Data

[62] Division of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,330,101, which is a continuation of Ser. No. 590,274, Sep. 28, 1990, abandoned, and a continuation of Ser. No. 310,252, Feb. 13, 1990, abandoned, which is a continuation of Ser. No. 290,975, Dec. 28, 1988, abandoned.

[51] Int. Cl.⁶ C07H 21/04

[52] U.S. Cl. 536/23.53; 530/387.3;
 435/320.1; 435/252.3

[58] Field of Search 536/23.53; 530/387.3;
 435/320.1, 252.3

[56] References Cited

U.S. PATENT DOCUMENTS

4,578,335	3/1986	Urdal et al.	530/351
4,816,397	3/1989	Boss et al.	435/68
4,816,363	3/1989	Honjo et al.	43-19.1
4,816,367	3/1989	Cabilio et al.	536/387
4,843,198	7/1989	Urdal et al.	530/387
4,867,973	9/1989	Gors et al.	424/83.91
5,194,359	3/1993	Taniguchi et al.	435/252.3
5,225,539	7/1993	Winter	530/387.3
5,476,786	12/1993	Huston et al.	435/63.8

FOREIGN PATENT DOCUMENTS

0 120 694	10/1984	European Pat. Off.
0171496	2/1986	European Pat. Off.
0173494	3/1986	European Pat. Off.
0184187	6/1986	European Pat. Off.
0256654	7/1987	European Pat. Off.
0229400	9/1987	European Pat. Off.
0266663	6/1988	European Pat. Off.
0 323 806	7/1989	European Pat. Off.
0 328 404	8/1989	European Pat. Off.
0 363 209	4/1990	European Pat. Off.
0 365 997	5/1990	European Pat. Off.
0 123 023	6/1991	European Pat. Off.
0460167	12/1991	European Pat. Off.
2188941	10/1997	United Kingdom
8928874	12/1999	United Kingdom
WO 8603513	9/1986	WIPO
WO 87/02671	5/1987	WIPO
WO 88/09344	12/1988	WIPO
WO 89/01783	3/1989	WIPO
9109967	7/1991	WIPO

OTHER PUBLICATIONS

Better et al. "Escherichia coli Secretion of an Active Chimeric Antibody Fragment." *Science*, 240:1041-1043

Bird et al., "Single-Chain Antigen-Binding Proteins," *Science*, 242:423-426 (1988).

Boulianne et al., "Production of functional chimeric mouse/human antibody," *Nature*, 312:643-646 (1984).

Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy," *Proc. Natl. Acad. Sci.*, 89:4285-4289 (1992).

Chothia, C. and A.M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987).

Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci.*, 88:2869-2873 (1991).

Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," *J. Immunol.*, 148:1149-1154 (1992).

Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids Res.*, 19:2471-2476 (1991).

Ellison et al., "The nucleotide sequence of a human immunoglobulin c(gamma)1 gene," *Nucleic Acids Res.*, 10:4071-4082 (1982).

Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," *Immunol. Rev.*, 63:129-166 (1982).

Foots et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.*, 224:487-499 (1992).

Gorman et al., "Reshaping a therapeutic CD4 antibody," *Proc. Natl. Acad. Sci.*, 88:4181-4185 (1991).

(List continued on next page.)

Primary Examiner—Lila Peisce

Assistant Examiner—Julie E. Reeves

Attorney, Agent, or Firm—Townsend and Townsend and Crew LLP

[57]

ABSTRACT

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.